ISSN: 2348 9510
**International Journal Of Core Engineering & Management (IJCEM)**
**Volume 2, Issue 9, December 2015**

# ALTERATION OF ATHEROSCLEROTIC PLAQUE BY STATIN THERAPY

**Dr. Syed Mohamed Ibrahim Sulthan**
(Ph.D., from Delhi University & Working at Shaqra University)
Bio-Medical Engineering Laboratory,
College of Engineering, Shaqra University,
Ad-Dawadimi, Riyad Province, Saudi Arabia
syed.mohamed@su.edu.sa

***ABSTRACT***
***A relationship exists among threat of cardiovascular disease (CVD) and circulating levels of lipoprotein low density cholesterol (LDL-c). Confirmation from clinical trials indicates that reducing LDL-c levels may result in useful clinical outcomes in patients in danger of CVD and in risky patients with clinical symptoms of CVD. Lipid-reducing agents, of that HMG-CoA reductase inhibitors (statins) are the foremost efficient, defend against the vascular changes found within the improvement of atherosclerotic plaque formation. Clinical experiments examining the consequences of statins on coronary atherosclerosis by means of quantitative coronary X-ray photography or intravascular ultrasound demonstrated that statins will reduce progression or perhaps cause regression of atherosclerotic plaque. This progress of anatomical structure once statin treatment is correlative with decrease in LDL-c levels. This seems to be the foremost mechanism by which statin therapy reduces cardiovascular hazard, with emerging proof for statin-mediated changes in HDL and C – reactive protein levels contributing to alteration of the atherosclerotic plaque***
***Keywords — Vascular changes, Lipid-reducing agents, atherosclerotic plaque, statin therapy, coronary.***

## I. INTRODUCTION

Cardiovascular disease (CVD) could be a leading reason behind death in developed countries [1]. According to National Institute for Statistics and Economic Studies reveals that 28.4% of all deaths are owing to CVD (2005) [2]. The leading general clinical presentation of cardiovascular disease is coronary cardiopathy (CHD) that explains for 500th of all CVD deaths within the developed countries compared with twenty fifth due to stroke [3].

The pathologic procedure of CVD is well understand and involves the progressive accretion of cholesterin inside the blood vessel wall, resulting in the development of atheromatic plaques that cause vascular narrowing. Eventually, the atheromatic plaque could rupture to cause vascular

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

occlusion which will proceed to serious conclusion such as myocardial infarction, stroke, heart disease, or peripheral arterial malady [4] [5].

The progression of atherosclerosis and thus risk of CVD is influenced by a range of risk factors, together with low levels of HDL-c [7] and elevated levels of LDL-c [6]. Elevated LDL-c plays a crucial role in atheromatic plaque development and rupture and progression of the plaque [4] that causes most of the acute symptoms of acute CHD.

Management of CVD involves a mixture of pharmacological interventions together with life-style changes to minimize adjustable risk factors, like dyslipidemia, high blood pressure, obesity, physical inactivity, and smoking [3]. Based on a huge amount of clinical indication, blood LDL-c levels are the foremost target of cholesterol minimizing therapy for primary and secondary deterrence of CVD, [6] with the maximum advantage derived from early intervention [8].

The aim of this work is to provide a short summary of the role of LDL-c in coronary-artery disease plaque development and of techniques for assessing plaque progression, so as to debate the impact of HMG-CoA reductase inhibitors (statins) on coronary-artery disease plaque, primarily via their impact on LDL-c.

## II. PATHOGENESIS OF ATHEROSCLEROSIS

Atherosclerosis could be a complex malady that typically develops many years before any clinical symptoms are manifest; it's originated by risk factors like diabetes mellitus, smoking, metabolic disorder, and high cholesterol diet [6]. Despite similar underlying pathological process mechanisms (described below), the clinical manifestations of fatty tissue plaques vary reckoning on the positioning of the plaque. Clinical events include ischaemic cardiovascular disease (coronary arteries), blood vessel occlusive malady (peripheral arteries), stroke (cerebral arteries), renal disorder (renal arteries), and arteria cardiovascular disease (aorta) [9].

The first phase of hardening of the arteries is epithelial tissue injury and disfunction that excites the accretion and oxidization of LDL-c within the vessel wall. Monocytes migrate from the blood into the sub-endothelial membrane and remodel into macrophages that collect macromolecular (lipids) to generate the lipid core of the arteriosclerosis plaque. Thrombotic and inflammatory phenomena are central to arteriosclerosis lesion development [5]. Production of inflammatory mediators and cytokines inspire relocation and propagation of smooth muscle cells of the vascular membrane, and deposition of extracellular matrix molecules like albuminoid and collagen, those results in plaque enlargement and therefore the fibrous cap development. Ultimately the fibrous cap might weaken and rupture, exposing the original thrombogenic tissues. Plaque rupture will cause continuing development of the arteriosclerosis lesion by causing additional coagulum creation and unleash of additional inflammatory mediators, leading to continuing Luminal narrowing. A lot of forceful outcome of plaque damage is blood vessel occlusion, which

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

may lead to myocardial infarct, ischemia, or crucial anaemia in peripheral tissues [4] [5].
Inflammatory phenomena assume a fundamental task in all stages of coronary artery disease,[5] as well as in plaque rupture resulting in acute ischaemic measures as proved by a major connection between the incidence of cardiovascular events and the levels of the inflammatory marker c-reactive protein (CRP) [10]. However, CRP may be a nonspecific marker of inflammation, and whether or not it plays an immediate role within the pathological process of coronary artery disease remains an issue of dialogue [11].

## III. MEASURING TOOLS FOR VASCULAR STRUCTURAL CHANGE

As the coronary-artery disease plaque develops, it usually enlarges outward, instead of invasive on the vessel lumen, so the malady is hidden till the incidence of considerable vascular medical measures at a later on phase [4] [5]. Thickening of the vessel wall might progress for several years before any tube-shaped structure clinical events occur, therefore, early detection of subclinical malady is vital to enhance treatment outcomes. Of the techniques accustomed assess the severity and progression of arteria malady (CAD), those utilized in studies with statins have typically been coronary X-ray photography or ultrasound (B-mode ultrasound or intravascular ultrasound [IVUS]).
By means of the non-invasive technique of high-resolution B-mode ultrasound, vessel wall structures are often visualised. The ultrasound image formed displays standard pattern correlating with the anatomical layers of the vessel barrage. Interface connecting the lumen-intima and therefore the media-adventitia is obviously represented and thickening are often seen as a standardized uniform pattern in straight blood vessel segments [12] [13] Changes in tube-shaped wall structure are frequently detected by computing the membrane thickness (IMT) of the arteria vessel partition. Intima-media thickening could be a direct indication of macromolecular (lipid) deposition within the tube-shaped structure wall. IMT are often identified as a surrogate marker for arteriosclerosis malady, as a extrapolative index for clinical CAD, and as a surrogate end point for concluding the success of intervention [12] [13] [14] [15].
Invasive coronary X-ray photography (quantitative coronary X-ray photography [QCA]) has historically been the strategy of selection for quantifying the severity and progression of coronary indurations of the arteries [16]. This method produces pictures solely of the tube-shaped structure lumen and is unable to observe plaque formation or changes within the tube-shaped structure wall [16]. In distinction, pictures of the plaque and tube-shaped structure wall are obtained using IVUS, [16] that is the most typical technique used for determining subclinical induration of the arteries progression within the arteria coronaria as a result of its preciseness and reliability [17]. IVUS provides an assessment of plaque volume [18]. For the judgment of coronary artery disease progression/regression IVUS volumetrical plaque burden can be used as an endpoint, and it also

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

being used basically in clinical studies of lipid-modifying techniques [19].

## IV. TARGETING LOW-DENSITY LIPOPROTEIN CHOLESTROL - CLINICAL ADVANTAGES

Epidemiologic studies have systematically established that LDL-c levels are associated with CVD risk. A log-linear relationship between exaggerated blood serum LDL-c levels and enhanced relative risk for CHD is verified by Grundy et al. [20]. The information premeditated during this method recommends that for each one mg/dL modification in LDL-c, the relative risk changes by one percentage [20]. Confirmation from controlled clinical trials for lowering LDL-c has substantiated a causative role for LDL-c in CVD and atherogenesis [6].

For coronary sickness preclusion, LDL-c levels are the key treatment target. According to the third report from NCEP ATP III the target LDL-c levels are given as follows:[20]

| **LDL-c** | **CVD risk** | **Factors %** |
|---|---|---|
| **100 mg/dL** | high-risk | CHD >20% |
| **130 mg/dL** | Moderate / moderately high risk | CHD>2 and 10–20% |
| **160 mg/dL** | lower risk | 0–1 CHD <10 % |

Although these procedure promote levels of lower than one hundred mg/dL in patients with high CVD risk, Grundy and colleagues encourage a fair lower LDL-c target of <70 mg/dL as a therapeutic decision in these patients [20]. Analysis of LDL-c levels in a very massive cohort of patients hospitalized for CAD (n = 8900) found a mean LDL-c level of 104.9 mg/dL at admission, with nearly one half of the cluster having levels lower than one hundred mg/dL [21] These findings recommend even additional support for smaller than suggested target LDL-c goals following macromolecular (lipid) lowering treatment [21].

There is growing substantiation to recommend that it's not absolutely the estimate of the LDL-c following reduction, however the proportion of reduction from initial pre-treatment values that's important, [22] [23] predominantly in elevated -risk patients with high LDL-c levels [20]. In a study, there was a scarcity of substantiation for the existence of a threshold for LDL-c for elevated -risk patients further than that lowering wouldn't minimize CVD risk [22]. Emerging substantiation additionally suggests a vital role for HDL-c in lowering CVD risk; a meta-analysis of twenty three trials (statin monotherapy studies- eleven trials) anticipated that a forty percentage reduction in LDL-c levels combined with a thirty percentage elevation in HDL-c would upshot in a seventy percentage reduction in CVD risk [24].

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

## V. ATHEROSCLEROTIC PLAQUE FORMATION REDUCED BY STATINS

Statins are the foremost frequently prescribed lipid-lowering agents. Different kind of statins is developed with slightly completely different pharmacological profiles [25]; but, all of the presently obtainable statins diminish LDL-c by 20–35%. The advantages of lipid-lowering medicine treatment materialize to be continued, as point out by a 4-year follow-up of the Heart Protection Study [26]. Reductions in LDL-c levels stimulated by statins were related to diminution within the prevalence of CVD events in primary and secondary preclusion trials, [3] [27] together with exceptional patient populations like patients with nephritic failure [28] or impairment [29]. This medical advantage could also be ascribed to the anti-atherogenic impact of statins that was assessed within the studies reviewed during this section by means of coronary X-ray photography or ultrasound techniques.

### A. Vascular Improvement - Angiographic Studies

It is thought that macromolecular (lipid)-lowering treatment reduces the macromolecular (lipid) content of arterial sclerosis lesions that contain a huge lipid core and plenty of membrane foam cells, and during this approach, such lesions are made higher stability [30]. One among the earliest studies of secondary preclusion in patients with angiographically confirmed CAD accounted a big (4.1%; $p = 0.005$) decrease in stricture diameter in those patients with a stricture of > fifty percentage at baseline; a thirty eight percentage decrease in LDL-c levels was additionally discovered (MARS [31]). The results of eleven secondary preclusion trials on the consequence of lipid-lowering remedy on coronary arterial sclerosis (assessed by means of QCA compute stricture diameter in arterial sclerosis lesions) were investigated by simple regression [32]. This analysis found that percentage reduction in LDL-c levels was strongly related to the modification in percent diameter stricture. These results recommend that the proportion in reduction in LDL-c levels correlates quite strongly with angiographic conclusion than complete LDL-c levels, and is additional important in preclusion of CHD by alleviating the arterial sclerosis plaque [32]. Regression analysis of supplementary studies indicate that each measurements are excellent predictors of angiographic advantage and additionally indicate an assistance in lipid-lowering remedy in spite of baseline LDL-c for patients with delicate to moderately elevated LDL-c levels [33].

Further confirmation that statin therapy promotes regression of disruptive CAD was obtained by examine the correlation between macromolecular (lipid) levels and also the progression of CAD within the ASTEROID trial [17]. Of the five hundred patients treated with rosuvastatin forty mg/day for twenty-four months, 292 patients underwent serial quantitative X-ray photography (secondary endpoint), had baseline stenoses >25%, and had stricture measurements at study conclusion [34]. Within this subgroup of patients, the mean percent diameter stricture reduced from baseline 37% to 36% ($p < 0.001$), and also the minimum lumen diameter

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

(MLD) enlarged from 1.65 to 1.68 millimetre ($p < 0.001$) following treatment with the lipid-lowering medicine. The changes in macromolecular (lipid) levels in response to lipid-lowering medicine treatment were a 53.3 percentage diminution in LDL-c levels, a 13.8 percentage augment in HDL-c levels, and a 58.2% reduction within the LDL-c/HDL-c fraction. The trial investigators noted that this lipid-modifying treatment halted malady progression or soothe the coronary stenoses; 94 of patients had stable malady or coronary atherosclerosis regression consistent with MLD and 97 of patients had stable disease reliable with percent diameter stricture [34]. The results of their analysis of angiographic information were according to those use IVUS assessment of coronary arteriosclerosis [17].

**B. Regression and Ultrasound Studies on Arteriosclerosis**

The useful effects of statins on anatomical structure have additionally been established in clinical trials by means of intravascular imaging to measure the deterioration or progression of arteriosclerosis right through treatment with statins [17] [19] [33] ,[35] [36] [37]. Regression analysis was accustomed examine the outcomes of studies by means of ultrasound to observe the result of lipid-lowering medicine remedy on arteriosclerosis by means of IMT as a surrogate marker. This analysis established that the modification in MLD was associated with each on-treatment LDL-c level and percentage modification in LDL-c [33]. In another study by means of IMT as a surrogate marker in 876 less-risk symptomless patient (the METEOR examination), patients delighted with rosuvastatin 40 mg/day for 24 months practiced arrest of IMT progression compared with placebo-treated patients who practiced IMT progression [35]. Additionally, there have been considerably better reductions in LDL-c levels and will increase in HDL-c levels in rosuvastatin than placebo recipients $p < 0.0001$).

The ASTEROID and also the REVERSAL studies were designed determine the consequences of statins on coronary malady progression. The REVERSAL study compared two lipid-lowering medicine regimens, one designed to provide moderate effects (pravastatin 40 mg) and therefore the alternative to provide intensive reduction in LDL-c levels (atorvastatin 80 mg) [19]. The ASTEROID learning employed one exhaustive administration (rosuvastatin 40 mg) to provide highest LDL-c reductions [17]. Each studies showed reductions in LDL-c levels, will increase in HDL-c levels, and a main deterioration of arteriosclerosis (computed by IVUS); within the REVERSAL study, the intensive regime provided huge reduction in development of arteriosclerosis weigh against with the moderate regime [19].

Conversely, consequence of the ASTEROID study point out that there's no apparent threshold for the advantages of LDL-c lowering on coronary-artery disease, which the degree of LDL-c reduction achieved with lipid-lowering drug treatment, is associated with the degree of regression of IMT. It is clear that atheromatic space at follow-up was considerably reduced from baseline IVUS levels during a patient receiving lipid-lowering drug treatment for 24 months [17]. Once regression-

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

analysis information from a similar study were compared with information from different recent IVUS regression-progression studies, a major association was found between LDL-c achieved and adipose tissue volume[17]. Coronary-artery disease progression was detained in patients receiving the intensive lipid-lowering drug treatment (atorvastatin 80 mg), however not in those receiving the moderate lipid-lowering drug treatment (pravastatin forty mg) within the REVERSAL study [19]. The ASTEROID study only explained a regression in coronary-artery disease compared with baseline in patients receiving intensive lipid-lowering drug treatment [17]. These interpretation sustain commendation for high-intense lipid-lowering treatment, significantly for speculative patients with established CHD [17]. So, once patients within the ASTEROID study were stratified by baseline macromolecular (lipid) levels into teams with higher than or below mean baseline levels, there was no distinction between these 2 teams within the proportion of patients who gone through lipid-lowering drug treatment by decrease in adipose tissue volume. This means that though all patients with established CHD could have the benefit of intensive lipid-lowering drug treatment, despite the consequences their baseline LDL-c levels [38].

In addition, the significance of patient age as a determinant of the response to statin-induced coronary-artery disease regression was evaluated in an analysis of pooled information from the REVERSAL and ASTEROID trials in addition as 2 unrelated main IVUS experiments (ACTIVATE and CAMELOT tests) [39]. Serial volumetrical IVUS data were weigh against older (above the median age of fifty seven years) or younger (at or underneath the average age of 57.8 years) patient teams. There was no distinction in plaque regression rates between these teams, despite the consequences baseline LDL-c levels. These results hold up by means of lipid-lowering drug treatment to reverse advanced coronary hardening of the arteries in adult patients [39].

The medical outcome of plaque deterioration has been examined in an IVUS regression-development study, within which a hundred sixty five patients were undergoing transdermal intervention for the treatment of CAD. Plaque regression was related to diminution of LDL-c following ten months' lipid-lowering drug treatment, and patients receiving statins had a lower incidence of latest plaque development (described as cardiovascular incident) than those not receiving statins [40].

Discussion so far has targeted on the impact of changes in LDL-c levels provoked by statins on hardening of the arteries progression. However, levels of HDL-c also are identified to be of significance within the deterrence of pathology [36]. Plaque regression in response to lipid-lowering drug treatment interrelated to a boost in HDL-c levels additionally to a decline in LDL-c levels [36]. The clinical treatment-provoked mean increase of 7.5% ($p < 0.01$ vs baseline) in HDL-c was reciprocally associated to ($p < 0.001$) with the speed of plaque development as measured by IVUS-detected changes within atheroma volume in a logical fallacy analysis that combined information

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

from four lipid-lowering drug trials [36]. It's been anticipated that HDL-c has athero-protective properties [41]. Thus, HDL-c levels ought to be targeted additionally to LDL-c levels so as to optimize treatment for patients with CHD [42].

The advantageous effects of statins on coronary hardening of the arteries progression are characterizable not solely to their effects on macromolecular (lipid) levels, however perhaps additionally since their anti-inflammatory drug properties. Lipid-lowering drug treatment (pravastatin 40 mg/day or lipid-lowering medicine 80 mg/day) for eighteen months was related to a twenty two percentage reduction in C-reactive protein levels in a very logical fallacy analysis of five hundred and two patients with angiographically established coronary malady [43]. The reduction in C-reactive protein levels was considerably associated with rates of progression of hardening of the arteries assessed by means of IVUS, with a coefficient of correlation of 0.11 for each total fatty tissue volume and % adipose tissue volume ($p = 0.02$ and 0.01, correspondingly). The association was somewhat feeble however still important in a statistical procedure. The reductions in LDL-c levels were additionally interrelated with hardening of the arteries progression. However, solely a feeble connection was establish among changes in LDL-c and C-reactive protein levels ($r = 0.13$, $p = 0005$) [43]. The investigators accomplished that statin-mediated changes in C-reactive protein are self-regulating of their macromolecular (lipid) - reducing phenomena; following adjustment for changes in lipid levels, their investigation indicated that the reduction in C-reactive protein was autonomously and considerably related to with the speed of progression of hardening of the arteries [43]. But, dialogue remains on whether or not the anti-inflammatory drug effects of statins are self-regulating of their lipid-lowering effects [44]**.** The exaggerated levels of total sterol, triglycerides, LDL, and low levels of high-density lipoprotein associated with fatness showing higher rate of risk of cardiovascular diseases in fatness [45]**.**

With many complications associated fatness, especially the macromolecular (lipid) abnormalities that are most appropriate reason for morbidity, and mortality, it's of importance, that the prevalence of fatness must be reduced. Early detection and deterrence of fatness and abnormal macromolecular (lipid) profile will facilitate to diminish morbidity, and mortality through rising public awareness concerning healthy life-style and food habit [45].

## VI. CONCLUSIONS

Numerous landmark trials have confirmed the advantages of lipid-lowering treatment in primary and secondary deterrence of CVD, and have shown a transparent correlation between reduced LDL-c levels and reduced risk of CVD. Statins are the foremost common pharmacological lipid-lowering therapies due to their established clinical result. Statins effectively scale back LDL-c levels, the first treatment target. The higher the reduction of LDL-c obtained with statins,

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

the bigger the reduction in progression or perhaps regression of coronary-artery disease plaque formation. Over the past twenty years, QCA and then IMT and IVUS have shown that statins alter the usual record of the malady. The clinical advantage of statins in all probability results from modification of the coronary-artery disease plaque via diminution of macromolecule content and action on inflammatory parameters.

**REFERENCES**


- European mortality database [online database]. Copenhagen: WHO Regional Office for Europe, 2007 [online]. Available from URL: http://www.euro.who.int/InformationSources/Data/20011017_1 [Accessed 2009 Feb 26]
- National Institute for Statistics and Economic Studies (INSEE). France in facts and figures: main causes of death. 2008 [online]. Available from URL: http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATFPS06205 [Accessed 2009 Feb 26]
- National Institute for Health and Clinical Excellence. Technology Appraisal 94: statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardio-vascular disease [online]. Available from URL: http://www.nice.org.uk/Guidance/TA94 [Accessed 2009 Feb 26]
- Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr Mol Med 2001 Dec; 1 (6): 633–53
- Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007 Jan; 14 (1): 55–61
- NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143–421
- Gordon D, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8–15
- Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol lower risk of ischemic heart disease? BMJ 1994; 308: 367–72

ISSN: 2348 9510
**International Journal Of Core Engineering & Management (IJCEM)**
**Volume 2, Issue 9, December 2015**


- Saini HK, Xu YJ, Arneja AS, et al. Pharmacological basis of different targets for the treatment of atherosclerosis. J Cell Mol Med 2005 Oct–Dec; 9 (4): 818–39
- PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43
- Tuzcu EM, Nicholls SJ. Statins: targeting inflammation by lowering low-density lipoprotein. J Am Coll Cardiol 2007; 49 (20): 2010–2
- Sankatsing RR, de Groot E, Jukema JW, et al. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005 Aug; 16 (4): 434–41
- Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the advisory board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23 (1): 75–80
- Bisoendial RJ, Hovingh GK, de Groot E, et al. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr Opin Lipidol 2002 Dec; 13 (6): 595–603
- Staub D, Meyerhans A, Bundi B, et al. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke 2006 Mar; 37 (3): 800–5
- Berry C, L'Allier PL, Gregoire J, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2008; 115: 1851–7
- Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr 5; 295 (13): 1556–65
- Brown BG, Zhao X-Q. Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression? J Am Coll Cardiol 2007; 49 (9): 933–8
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071–80

ISSN: 2348 9510
**International Journal Of Core Engineering & Management (IJCEM)**
**Volume 2, Issue 9, December 2015**


- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227–39
- Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 2009 Jan; 157 (1): 111–7.e2
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360 (9326): 7–22
- Patel T, Usmani A, Bavry A, et al. Relationship between intensive statin therapy and cardiovascular outcomes in patients with stable coronary artery disease: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 245
- Brown BG, Stukovsky KH, Zhao X-Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardio-vascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized trials. Curr Opin Lipidol 2006; 17: 631–6
- Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997 May; 32 (5): 403–25
- Bulbulia R, Bowman L, Wallendszus K. MRC/BHF Heart Protection Study (HPS): mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 393
- Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 Jun 28; 326 (7404): 1423
- Balamuthusamy S, Molnar J, Adigopula S. Statins decrease the risk of acute myocardial infarction and coronary heart disease mortality in patients with renal failure. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 188–9
- Saha S, Saremi A, Velasquez-Cecena J-L. Statins reduce the risk of death and the occurrence of adverse cardiovascular events in patients with dyslipidemia and renal dysfunction: a meta-analysis of randomized placebo-controlled trials. Am J Cardiol 2007; 49 (9 Suppl. A): 344

ISSN: 2348 9510
**International Journal Of Core Engineering & Management (IJCEM)**
**Volume 2, Issue 9, December 2015**


- Brown BG, Zhao X-Q, Sacco DE, et al. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 1993; 69 Suppl.: S48–53
- Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119 (10): 966–76
- Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995 Dec; 6 (6): 386–8
- Ballantyne CM, Herd JA, Dunn JK, et al. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997 Dec; 8 (6): 354–61
- Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008; 117: 2458–66
- Crouse J, Grobbee D, O'Leary D, on behalf of the METEOR Study Group. Rosuvastatin arrests progression of carotid intima media thickness in low risk individuals: main results of the METEOR study. Am J Cardiol 2007; 49 (9 Suppl. A): 392–3
- Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297 (5): 499–508
- O'Keefe Jr JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004 Jun 2; 43 (11): 2142–6
- Nicholls SJ, Sipahi I, Crowe T. Baseline lipid status does not influence the promotion of coronary atheroma regression in response to use of high dose statin therapy: insights from ASTEROID. Am J Cardiol 2007; 49 (9 Suppl. A): 365
- Sipahi I, Tuzcu M, Nicholls SJ. Regression of coronary atherosclerosis during treatment with statins: does age make a difference? Am J Cardiol 2007; 49 (9 Suppl. A): 336
- Takashima H, Asai K, Wakita Y. Impact of HMG-CoA reductase inhibitors (statins) on new cardiovascular events following coronary intervention and on the progression-regression of

ISSN: 2348 9510
International Journal Of Core Engineering & Management (IJCEM)
Volume 2, Issue 9, December 2015

coronary atherosclerotic plaque: a three-dimensional intravascular ultrasound study. Am J Cardiol 2007; 49 (9 Suppl. A): 325

- Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706–14
- Nicholls SJ, Tuzcu EM, Sipahi I. Statin-mediated increases in HDL cholesterol promote regression of coronary atherosclerosis: insights from intravascular ultrasound. Am J Cardiol 2007; 49 (9 Suppl. A): 365
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005; 352 (1): 29–38
- Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. J Am Coll Cardiol 2007; 49 (20): 2003–9
- Ibrahim Sulthan S. M. Atherosclerosis and Macromolecular Lipoproteins. International Journal of Emerging Research in Management &Technology 2015; 4 (11): 95-97 http://www.ermt.net/docs/papers/Volume_4/11_November2015/V4N11-152.pdf